Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Slideshows|January 20, 2015
Best of Times in Liver Diseases
Author(s)Gregory W. Rutecki, MD
There has been an explosion of diagnostic and therapeutic discoveries affecting the liver. In this slide show: key points on 5 important clinically relevant areas.
Advertisement
There has been an explosion of diagnostic and therapeutic discoveries affecting the liver -- an essential organ, and common target of diseases seen in primary care. In this arena, it's the best of times.Leading a distinguished list of advances is the brave new world of interferon-free treatments for Hepatitis C.1I recently had the privilege of attending a “Liver Update”2 at the Cleveland Clinic. Here, I summarize 5 important areas that were-- and will continue to be -- clinically relevant.
Advertisement
Related to this article
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
3
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
4
FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke
5